Boehringer In­gel­heim ties the knot with Num­ab on new an­ti­bod­ies; Ca­balet­ta inks pact with Ar­ti­san

→ Switzer­land’s Num­ab Ther­a­peu­tics has added Boehringer In­gel­heim to its ros­ter of col­lab­o­ra­tors. And they will start with two projects aim­ing at de­vel­op­ing new drugs for dif­fi­cult-to-treat lung and gas­troin­testi­nal can­cers and pa­tients with ge­o­graph­ic at­ro­phy. “Num­ab’s tech­nol­o­gy plat­form fits well with our in­ter­nal an­ti­body dis­cov­ery and en­gi­neer­ing ca­pa­bil­i­ties and will en­hance our ef­forts to de­liv­er trans­for­ma­tive an­ti­body-based ther­a­peu­tics to pa­tients,” said Paige Ma­haney, an SVP at Boehringer In­gel­heim.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.